NEW ORLEANS--(BUSINESS WIRE)--ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS: CELG). Investor losses must relate to purchases of the Company’s shares between January 12, 2015 and February 27, 2018. This action is pending in the United States District Court for the District of New Jersey.
Celgene investors should visit us at https://www.claimsfiler.com/cases/view-celgene-corporation-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
On February 27, 2018, the Company revealed that the U.S. Food and Drug Administration had issued a refusal-to-file letter rejecting the New Drug Application (“NDA”) for Ozanimod, one of its leading drug candidates, because “the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.” On this news, the price of Celgene’s shares plummeted.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.